Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Small-molecule inhibitor of both type I and type II 5-alpha-reductase, supplied as oral capsules

Dutasteride — evidence

What has been published, classified by the kind of document it is. This is not a protocol, not a score, and not a recommendation for use.

Evidence overview

1 record in this file

  • REVIEW1

Research areas. Approved hair-loss treatment.

Publication span. 2022.

What we know

    Editorial reading of the records below, labelled as Therapept analysis. How records are built

    What remains uncertain

      Regulatory notes

      FDA-approved drug substance

      • FDA-approved in the United States for benign prostatic hyperplasia. Therapept found no FDA-approved dutasteride product for androgenetic alopecia.
      • A 2022 review records that Japan and South Korea have approved oral dutasteride 0.5 mg daily for male androgenetic alopecia, while United States use for hair loss remains off-label.
      • Dutasteride has a long half-life relative to finasteride; the label's warnings and precautions apply. Regulatory status is not a safety assessment.

      Regulatory status describes how a substance is classified. It is not a safety assessment of any particular material.

      Studies and documents

      1. REVIEW2022Narrative review

        Comparison of oral minoxidil, finasteride and dutasteride for treating androgenetic alopecia

        Gupta AK, Talukder M, Williams GJournal of Dermatological Treatment

        Population
        Adults with androgenetic alopecia
        Objective
        To compare oral minoxidil, finasteride and dutasteride for androgenetic alopecia.
        Endpoint investigated
        Efficacy and safety as reported across the reviewed literature

        The review notes that oral finasteride 1 mg is FDA-approved for male androgenetic alopecia, while oral minoxidil and oral dutasteride are not approved for that use in the United States. It records that Japan and South Korea have approved oral dutasteride 0.5 mg daily for male androgenetic alopecia.

        Limitations. Narrative review, not a new trial. Its proposed efficacy ordering is the authors' interpretation of heterogeneous studies, not a head-to-head result, and should not be read as a prescribing recommendation.

        DOI 10.1080/09546634.2022.2109567Gupta et al., J Dermatolog Treat (2022) — PubMed 35920739Reviewed 13 November 2026

      Last reviewed 13 November 2026 · Compiled by Therapept Editorial · How these records are built